Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004084 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
A Phase 1 study, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00004084: Completed Phase 1 study, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
NCT00004084 is a Phase 1 study that has completed, run by Garden State Cancer Center at the Center for Molecular Medicine and Immunology. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004084, a Phase 1 study, has completed, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have lymphoma or leukemia that has not responded to previous chemotherapy.
Interventions
- RADIATION indium In 111 LL2 IgG
- RADIATION yttrium Y 90 epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 1998-04 |
| Phase | Phase 1 |
Sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology6 total trials
What the finished NCT00004084 record still lists
NCT00004084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which indium In 111 LL2 IgG is the first listed.
NCT00004084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004084 about?
NCT00004084 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia". RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have lymphoma or leukemia that ...
What is the current status of trial NCT00004084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 1998-04.
What interventions are being tested in trial NCT00004084?
The interventions under investigation include: indium In 111 LL2 IgG (RADIATION), yttrium Y 90 epratuzumab (RADIATION).
Who is sponsoring clinical trial NCT00004084?
This trial is sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004084's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia